Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Avalon Healthcare Solutions Has Been Recapitalized by WindRose Health Investors

    William Blair acted as the exclusive advisor to Avalon Healthcare Solutions, a portfolio company of Francisco Partners, Blue Cross Blue Shield South Carolina, Echo Health Ventures, and HCSC Ventures, in connection with its majority recapitalization by WindRose Health Investors.

    Read more

  • Positioning for Growth in 2026: Policy Clarity, AI Momentum, and Sector Opportunities

    With investment momentum building, 2026 offers cautious optimism powered by AI innovation, clearer policy frameworks, and emerging sector prospects.

    Read more

  • Lawn Care’s Expansion Into Pest Control, Broader Outdoor Recurring Services

    Lawn care companies are evolving into broader outdoor services platforms. Jack Williams from William Blair’s Investment Banking consumer products & services team delves into what’s behind this evolution and how it is stoking transaction activity.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures